Seraseq® NTRK Fusion RNA Mix

Neurotrophic tyrosine receptor kinases (NTRK) can become abnormally fused to other genes resulting in growth signals that can lead to cancer in many organs of the human body. Anti-tumor drugs that target NTRK fusions have been shown to be largely effective across many tumor types regardless of patient age (adult or pediatric), especially in locally advanced or metastatic solid tumors. This product expands SeraCare's RNA Fusion FFPE reference material product portfolio to support routine clinical diagnostic / companion diagnostic (CDx) use for solid tumor testing of tissue biopsies for NTRK fusion genes in cancer disease diagnosis and treatment selection.

• 15 clinically-relevant NTRK fusion genes in a single reference sample
• Offered as purified RNA (spike-in mix) or FFPE for full process NGS assay validation and positive sample control
• Fusions precisely quantitated with digital PCR
• Well-characterized GM24385 human genomic RNA as background wild-type material
• Manufactured in GMP-compliant and ISO 13485-certified facility.

Specifications

Documents

• Seraseq NTRK Fusion RNA Reference Materials (Product Sheet)
• Seraseq NTRK Fusion RNA Mix Product Insert (Package Insert)
• Technical Spreadsheet for Seraseq NTRK Fusion RNA Reference Materials (Technical Spreadsheet)
• Seraseq NTRK Fusion RNA Mix Non-Requirement Letter (SDS Non-Requirement Letter)

Ordering Information